Roche announces statistically and clinically significant results from its phase III STARGLO study, demonstrating that Columvi significantly prolongs survival in patients with relapsed or refractory diffuse large B-cell lymphoma.

The study achieved its primary endpoint of overall survival, with a 41% reduction in the risk of death in patients treated with Columvi plus GemOx chemotherapy, compared with MabThera/Rituxan in combination with GemOx.

"This Columvi combination could provide a much-needed off-the-shelf treatment option for people with relapsed or refractory LDGCB who are not eligible for transplantation", the Swiss healthcare giant points out.

These data were presented at the press conference and presented at the plenary abstracts session of the European Hematology Association (EHA) 2024 Congress as a last-minute oral presentation.

Copyright (c) 2024 All rights reserved.